Provided by Tiger Fintech (Singapore) Pte. Ltd.

Annovis Bio, Inc.

1.60
+0.02001.27%
Post-market: 1.620.0200+1.25%16:26 EDT
Volume:299.22K
Turnover:480.30K
Market Cap:31.18M
PE:-0.69
High:1.68
Open:1.58
Low:1.56
Close:1.58
Loading ...

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

GlobeNewswire
·
14 Jan

Annovis Bio: Strategic Advancements and Phase 3 Trial Acceleration Justify Buy Rating

TIPRANKS
·
09 Jan

Annovis Bio Says FDA Approved Revised Protocol for Phase 3 Alzheimer's Disease Study

MT Newswires Live
·
08 Jan

BUZZ-Annovis Bio rises as FDA approves late-stage Alzheimer's study protocol

Reuters
·
07 Jan

Annovis Bio announces FDA acceptance of protocol for Phase 3 AD study

TIPRANKS
·
07 Jan

BRIEF-FDA Accepts Final Protocol For Pivotal Phase 3 Alzheimer’S Disease Study, Streamlining Development Pathway

Reuters
·
07 Jan

FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway

THOMSON REUTERS
·
07 Jan

Annovis Bio Inc - Revised Protocol Includes 6-Month Symptomatic and 12-Month Disease-Modifying Assessment

THOMSON REUTERS
·
07 Jan

Annovis Bio Inc - Integrates Phase 3 Ad Studies Into Single 6/18-Month Trial

THOMSON REUTERS
·
07 Jan

FDA Accepts Final Protocol for Pivotal Phase 3 Alzheimer’s Disease Study, Streamlining Development Pathway

GlobeNewswire
·
07 Jan

BUZZ-Annovis Bio falls on planned $50 mln share sale

Reuters
·
11 Dec 2024

BRIEF-Annovis Bio Enters Equity Distribution Agreement With Oppenheimer

Reuters
·
11 Dec 2024

Annovis Bio Inc - to Offer up to $50 Million in Common Stock

THOMSON REUTERS
·
11 Dec 2024

Annovis Bio Inc - Enters Equity Distribution Agreement With Oppenheimer

THOMSON REUTERS
·
11 Dec 2024

Annovis Bio Inc - Appoints William Fricker as Interim CFO

THOMSON REUTERS
·
10 Dec 2024

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today’s Marketplace

GlobeNewswire
·
05 Dec 2024

Annovis to Host Year-End Investor Webcast on December 11, 2024

GlobeNewswire
·
25 Nov 2024

Strategic Buy Rating on Annovis Bio Amid Regulatory Alignment and Growth Potential in Alzheimer’s Market

TIPRANKS
·
15 Nov 2024

Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)

GlobeNewswire
·
12 Nov 2024

Annovis Bio GAAP EPS of -$0.97 misses by $0.58

seekingalpha
·
11 Nov 2024